CD8A and neoplasm: Antibody-cytokine fusions with tumor-homing properties are likely to display their therapeutic action and to increase the therapeutic index of the corresponding cytokine payload as a result of a specific activation and proliferation of tumor-resident CD8+ T cells and of NK cells, which recognize malignant structures (2, 3).